Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™

SOUTH PLAINFIELD, NJ, April 14, 2015 /PRNewswire/ -- Prolong announced today that it had presented data on its flagship product SANGUINATE, reporting its novel ability to rapidly reverse sickling of human red blood cells...

Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA

SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its flagship product SANGUINATE...

Prolong Expands Operations (& Potential for Success)

Prolong recently announced the expansion of its South Plainfield, New Jersey, biologics processing facility, adding 24,000 square feet in a move that essentially doubles its original manufacturing capacity to 48,000 square feet...

Prolong Pharmaceuticals Moves Into New Headquarters

Prolong Pharmaceuticals LLC announced the expansion of its South Plainfield, N.J., manufacturing facility. A new long-term lease on the space adjoining its current facility is adding 24,000 square feet to the existing 24,000 square feet. In addition, the company secured 12,000 square feet of new executive and administrative space...

Father of PEGylation to Receive Dr. Sol J. Barer Award at Gateway Gala, BioNJ’s 22st Annual Dinner Meeting, Networking Event and Innovation Celebration

Abraham Abuchowski, Ph.D., considered the father of PEGylation...

Use of SANGUINATE in encephalopathy from severe sickle cell disease

Patients with sickle cell anemia (SCD) are at increased stroke risk. Periodic blood transfusions decrease tim-averaged mean of the maximum velocities of...

Strategic Approach Needed for International Clinical Trials

Over the past two decades, the decision process for siting overseas clinical trials has become more complex for U.S. pharmaceutical companies. Once a straightforward analysis rooted in time and money, longer-term strategic issues...

Sickle Cell Disease In Three Acts

The first act in the story of sickle cell disease, one of the oldest known genetic diseases, is not a happy one. Aside from a very small number of young patients undergoing successful bone marrow or stem cell transplants, there is no curative treatment...

Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced...

Prolong’s approach: Taking on multiple diseasesCompany confident Sanguinate can be difference-maker

Attacking one disease is challenging enough, but what if you can attack a disease that produces multiple disorders? Answering that question motivates Prolong Pharmaceuticals LLC, a South Plainfield biotech company developing...